Q-omics provides the consensus-scored DPPA2 profile across patient tissues and cancer cell-line models. DPPA2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, DPPA2 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, DPPA2 RNA expression shows 11,919 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where DPPA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPPA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPPA2 survival associations across molecular data types. DPPA2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPPA2 RNA expression–survival associations across cancer types. High DPPA2 expression shows unfavorable associations in COAD, MESO, LAML and DLBC, but favorable associations in SCLC and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for DPPA2 RNA expression.
This table summarizes DPPA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DPPA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPPA2 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUSC, HNSC and UCEC. The KIRC box plot shows higher DPPA2 RNA expression in normal versus tumor tissue (log2 FC = −0.546, t-test p < 0.001).
This table shows molecular features associated with DPPA2 in patient tissues and cancer cell lines. In patient samples, DPPA2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DPPA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
